Results
|
|
1.
|
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. MedStar authors:
Year: 2015
Citation: - Lancet Oncology. 16(9):1037-48, 2015 Sep.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Liu Q, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
|
|
|
2.
|
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(12):1719-1729, 2019 12.
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Blay JY, Chawla S, Choy E, Dai T, Gelderblom H, Grimer RJ, Henshaw R, Jandial D, Le Cesne A, Palmerini E, Reichardt P, Rutkowski P, Schuetze SM, Seeger L, Skubitz K
|
|
|
3.
|
Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI). MedStar authors:
Year: 2021
Citation: - Oncology. 99(1):41-48, 2021.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Bijelic L, de Hingh I, Glatzer M, Glehen O, Goere D, Haller L, Li Y, Moran BJ, Morris DL, Piso P, Putora PM, Quadros CA, Rau B, Steffen T, Sugarbaker P, Yonemura Y
|
